| Drug General Information |
| Drug ID |
D0O9II
|
| Former ID |
DNC003588
|
| Drug Name |
[1,3]Thiazinan-(2E)-ylideneamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C4H8N2S
|
| Canonical SMILES |
C1CN=C(SC1)N
|
| InChI |
1S/C4H8N2S/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
|
| InChIKey |
PQXQEOIFIUJLIE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
| Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
Phagosome
|
|
Circadian entrainment
|
|
Long-term depression
|
|
Salivary secretion
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)hsa00220:Arginine biosynthesis
|
|
HIF-1 signaling pathway
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancerhsa00330:Arginine and proline metabolism
|
|
cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
NetPath Pathway
|
EGFR1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map STP00005:Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
Monoamine Transport
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Alzheimers Disease
|
|
Effects of Nitric Oxide
|
|
Serotonin Transporter ActivityWP619:Type II interferon signaling (IFNG)
|
|
AGE/RAGE pathway
|
|
Effects of Nitric OxideWP554:ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Metabolism of nitric oxide
|
|
Angiogenesis
|
| References |
| REF 1 | J Med Chem. 1996 Feb 2;39(3):669-72.2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. |
|---|
